# US 2014/0193451 A1 · Immunogenic composition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193451 A1 - Document ID: US20140193451A1 - Status: Published application - Kind: A1 - Application number: 13/826,932 - Filed: 2013-03-14 - Published: 2014-07-10 - Earliest claimed: 2012-10-17 - Assignees: Glaxosmithkline Biologicals SA - Applicants: Glaxosmithkline Biologicals SA - Inventors: VINCENT VERLANT - Web page: https://patentgrep.com/patent/US20140193451A1 ## CPC - A61K 39/092: {Streptococcus} - A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to immunogenic compositions comprising 26 μg-45 μg of pneumolysin and/or PhtD, vaccines comprising the immunogenic compositions and their use in medicine. ## Claims ### Claim 1 An immunogenic composition comprising 26 μg-45 μg, 26 μg-40 μg, 28 μg-35 μg or around 30 μg of detoxified pneumolysin (dPly) and/or PhtD (polyhistidine triad family D), per human dose. ### Claim 2 (depends on 1) The immunogenic composition of claim 1 wherein the pneumolysin has been chemically detoxified. ### Claim 3 (depends on 1) The immunogenic composition of claim 1 wherein the pneumolysin has been genetically detoxified. ### Claim 4 (depends on 1, 2, 3) The immunogenic composition of any one of claims 1-3 wherein the PhtD (poly histidine triad family D) comprises an amino acid sequence at least 85%, 90%, 95%, 98%, 99% or 100% identical to the sequence of amino acids 21-838 of Sequence ID No. 4 of WO00/37105. ### Claim at position 5 5-15. (canceled) ### Claim 16 The immunogenic composition of any preceding claim wherein the immunogenic composition does not comprise an oil in water adjuvant. ### Claim at position 7 17-19. (canceled) ### Claim 20 The immunogenic composition of any preceding claim wherein the immunogenic composition further comprises 1 or more (e.g. 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) Streptococcus pneumoniae capsular saccharide conjugates. ### Claim 21 (depends on 20) The immunogenic composition of claim 20 wherein the 1 or more Streptococcus pneumoniae capsular saccharide conjugates comprises a conjugated serotype 4 saccharide, a conjugated serotype 6B saccharide, a conjugated serotype 9V saccharide, a conjugated serotype 14 saccharide, a conjugated serotype 18C saccharide, a conjugated serotype 19F saccharide and a conjugated serotype 23F saccharide. ### Claim 22 (depends on 20, 21) The immunogenic composition of claim 20 or 21 wherein the 1 or more Streptococcus pneumoniae capsular saccharide conjugates comprises a conjugated serotype 1 saccharide, a conjugated serotype 5 saccharide and a conjugated serotype 7F saccharide. ### Claim at position 11 23-35. (canceled) ### Claim 36 (depends on 20, 21, 22) The immunogenic composition of any one of claims 20-22 wherein the 1 or more Streptococcus pneumoniae capsular saccharide conjugates are conjugated to a carrier protein independently selected from the group consisting of tetanus toxoid (TT), fragment C of TT, diphtheria toxoid (DT), CRM197 (cross reacting material 197), detoxified pneumolysin, protein D from H. influenzae, PhtD (Poly Histidine Triad D), PhtDE (fusion protein between Poly Histidine Triad D and Poly Histidine Triad E) and N19. ### Claim 37 (depends on 20, 21, 22, 36) The immunogenic composition of any one of claim 20-22 or 36 wherein the 1 or more Streptococcus pneumoniae capsular saccharide conjugates are all independently conjugated to CRM197. ### Claim at position 14 38-50. (canceled) ### Claim 51 (depends on 20, 21, 22, 36, 37) The immunogenic composition of any one of claim 20-22 or 36-37 wherein the 1 or more Streptococcus pneumoniae capsular saccharide conjugates comprises a serotype 1 saccharide conjugated to protein D, a serotype 4 saccharide conjugated to protein D, a serotype 5 saccharide conjugated to protein D, a serotype 6B saccharide conjugated to protein D, a serotype 7F saccharide conjugated to protein D, a serotype 9V saccharide conjugated to protein D, a serotype 14 saccharide conjugated to protein D, a serotype 23F saccharide conjugated to protein D, a serotype 18C saccharide conjugated to tetanus toxoid and a serotype 19F saccharide conjugated to diphtheria toxoid. ### Claim at position 16 52-61. (canceled) ### Claim 62 The immunogenic composition of any preceding claim which further comprises an adjuvant. ### Claim 63 (depends on 62) The immunogenic composition of claim 62 wherein the adjuvant is aluminium phosphate. ### Claim at position 19 64-65. (canceled) ### Claim 66 A vaccine comprising the immunogenic composition of any preceding claim and a pharmaceutically acceptable excipient. ### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 20, 21, 22, 36, 51, 62, 63, 64, 65, 66) A method of immunising a human host against diseases caused by Streptococcus pneumoniae infection comprising administering to the host an immunoprotective dose of the immunogenic composition of any one of claims 1-9, 20-22, 36, 51, 62-65 or the vaccine of claim 66. ### Claim 68 (depends on 67) The method of claim 67 wherein the host is selected from the group consisting of an adult human, and elderly human, an infant human and a toddler human. ### Claim at position 23 69-79. (canceled)